Celebrity Cancers Stoking Fear? Cisplatin Shortage Ends; Setback for Anti-TIGIT

— News, features, and commentary about cancer-related issues

Onco Break over a computer rendering of a cancer cell.

Are celebrity cancer diagnoses ? (Washington Post)

In related news, the rock band Heart postponed its tour after lead singer Ann Wilson . (CNN)

A new artificial intelligence tool can help physicians determine how a across multiple types of cancer. (Nature Cancer)

FDA Commissioner Robert Califf, MD, announced that cisplatin is . (Fierce Pharma)

Surveillance of individuals with a may lead to the detection of smaller, lower-stage tumors and improve survival. (JAMA Oncology)

The of lenalidomide (Revlimid)-refractory multiple myeloma showed that ciltacabtagene autoleucel (Carvykti) improved overall survival versus either pomalidomide (Pomalyst), bortezomib (Velcade), and dexamethasone, or daratumumab (Darzalex), pomalidomide, and dexamethasone, Legend Biotech announced.

A federal judge against a scientist who published a paper linking talc products to cancer. The judge determined the research was neither fraudulent nor libelous. (Reuters)

Cancer patients should stick to science-backed medicine and , the author of an opinion piece argued in Scientific American.

V. Craig Jordan, PhD, a pharmacologist who discovered that tamoxifen -- a failed contraceptive -- could block the growth of breast cancer cells, . (New York Times)

Adding the investigational TIGIT inhibitor tiragolumab to first-line atezolizumab (Tecentriq) plus chemotherapy for metastatic non-squamous non-small cell lung cancer versus pembrolizumab (Keytruda) plus chemotherapy in the SKYSCRAPER-06 trial, Roche announced; the company said it will discontinue the phase II/III study.

A Texas woman with sickle cell disease ; patients with the disease have an average life expectancy of 52 years. (NBC News)

Tracon Pharmaceuticals said it will for advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma after the pivotal ENVASARC trial failed to meet its primary endpoint.

  • author['full_name']

    Mike Bassett is a staff writer focusing on oncology and hematology. He is based in Massachusetts.